Page last updated: 2024-10-25

clomipramine and Visceral Pain

clomipramine has been researched along with Visceral Pain in 1 studies

Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.

Visceral Pain: Pain originating from internal organs (VISCERA) associated with autonomic phenomena (PALLOR; SWEATING; NAUSEA; and VOMITING). It often becomes a REFERRED PAIN.

Research Excerpts

ExcerptRelevanceReference
" This study was designed to evaluate whether the antinociception induced by NSAIDs could be modulated by clomipramine or risperidone using a chemical model of inflammatory acute visceral pain, the abdominal acetic acid induced a writhing test in mice."7.91Pharmacological interaction between NSAIDS with clomipramine and risperidone in mice visceral pain. ( Miranda, HF; Noriega, V; Prieto, JC; Sierralta, F; Vargas, CG, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vargas, CG1
Miranda, HF1
Sierralta, F1
Noriega, V1
Prieto, JC1

Other Studies

1 other study available for clomipramine and Visceral Pain

ArticleYear
Pharmacological interaction between NSAIDS with clomipramine and risperidone in mice visceral pain.
    Drug development research, 2019, Volume: 80, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clomipramine; Dose-Response Relationship, Drug; Dr

2019